Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303569 | 0.83 | CHRNA7 (0.38) | CHRNA7EZH2HDAC6KDM4EALDH1A1 | |
| SCHEMBL6305365 | 0.83 | CHRNA7 (0.41) | CHRNA7EZH2KDM4EALDH1A1EPHX2 | |
| SCHEMBL6306317 | 0.82 | CHRNA7 (0.37) | CHRNA7EZH2HDAC6KDM4EALDH1A1 | |
| SCHEMBL6303618 | 0.81 | CHRNA7 (0.34) | CHRNA7EZH2HDAC6KDM4EALDH1A1 | |
| SCHEMBL7122497 | 0.81 | CHRNA7 (0.36) | CHRNA7EZH2HDAC6EPHX2MMP2 | |
| SCHEMBL6303374 | 0.81 | CHRNA7 (0.56) | CHRNA7EZH2ALDH1A1EPHX2MMP2 | |
| SCHEMBL6303387 | 0.80 | CHRNA7 (0.36) | CHRNA7EZH2HDAC6 | |
| SCHEMBL6310723 | 0.80 | CHRNA7 (0.46) | CHRNA7EZH2 | |
| SCHEMBL6304623 | 0.79 | CHRNA7 (0.35) | CHRNA7EZH2HDAC6 | |
| SCHEMBL6310234 | 0.79 | MMP2 (0.39) | EZH2ALDH1A1MMP2MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | NAT1, CYP7A1, CYP7B1 | CHRNA7 2937/4885EZH2 4701/4885HDAC6 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.